Sunday 18 October 2026
Export BBOT’s income statement to Excel — free account
BridgeBio Oncology Therapeutics, Inc
BBOT Healthcare Biotechnology
In the quarter to June 2026, EPS fell 25.3% and free cash flow fell 88.8%, each against the same quarter a year earlier.
2.82
0.13
−4.41%
Follow BBOT
Target Price Range
Analyst price targets
Free accountTen years at a glance
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Trend | 2026e | 2027e | 2028e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | — | — | — | — | — | — | — | — | 10.03 | 8.50 |
Analyst estimates 2026–2028 Powerpack |
|||
| High | — | — | — | — | — | — | — | — | 11.59 | 14.87 | |||||
| People | |||||||||||||||
| People | Employees | — | — | — | — | — | — | — | — | — | 92 | ||||
| Revenue/emp, $m | — | — | — | — | — | — | — | — | — | 0.00 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | ||||
| Gross margin, % | — | — | — | — | — | — | — | — | — | — | |||||
| EBT | — | — | — | — | — | — | — | — | (74) | (134) | |||||
| EBT margin, % | — | — | — | — | — | — | — | — | 0.00 | 0.00 | |||||
| Net income | — | — | — | — | — | — | — | 0 | (74) | (134) | |||||
| Depreciation | — | — | — | — | — | — | — | — | 0 | 1 | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | — | — | — | — | — | — | — | — | 0.00 | 0.00 | ||||
| Earnings | — | — | — | — | — | — | — | — | (5,756.41) | (4.30) | |||||
| Cash flow | — | — | — | — | — | — | — | — | (4,265.66) | (3.66) | |||||
| Capex | — | — | — | — | — | — | — | — | (3.80) | (0.02) | |||||
| Free cash flow | — | — | — | — | — | — | — | — | (4,269.46) | (3.68) | |||||
| Book value | — | — | — | — | — | — | — | — | (13,847.83) | 13.20 | |||||
| Shares, m | — | — | — | — | — | — | — | — | 0 | 31 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | ||||
| P/S | — | — | — | — | — | — | — | — | — | — | |||||
| P/B | — | — | — | — | — | — | — | — | — | — | |||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | |||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | — | — | — | — | (55) | (114) | ||||
| Capex | — | — | — | — | — | — | — | — | 0 | (1) | |||||
| Free cash flow | — | — | — | — | — | — | — | — | (55) | (114) | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | — | — | — | — | — | — | — | — | 139 | 397 | ||||
| Total debt | — | — | — | — | — | — | — | — | — | — | |||||
| Net debt | — | — | — | — | — | — | — | — | (156) | (425) | |||||
| Shareholders’ equity | — | — | — | — | — | — | — | — | (179) | 411 | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | — | — | — | — | — | — | — | — | (90.41) | (43.76) | ||||
| ROIC | — | — | — | — | — | — | — | — | 0.00 | 0.00 | |||||
| ROE | — | — | — | — | — | — | — | — | 0.00 | (115.33) | |||||
Negative figures in brackets.
Charts ten years each
BridgeBio Oncology Therapeutics, Inc vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| ACIU AC Immune | $249.4M | — (loss-making) | — (loss-making) | +29.66% (above 0%: growing) | n/m | +4.66% (above 0%: growing) | 100.00% | (1,321.50%) | Compare |
| BBOT BridgeBio Oncology Therapeutics, Inc | $236.5M | — (loss-making) | — | — | n/m | −88.78% (below 0%: shrinking) | — | 0.00% | |
| SABS SAB Biotherapeutics, Inc. | $235.7M | — (loss-making) | 19.9× | −90.95% (below 0%: shrinking) | n/m | −59.75% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| IMRX Immuneering Corporation | $235.5M | — (loss-making) | — (loss-making) | −99.74% (below 0%: shrinking) | n/m | −74.94% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| QTTB Q32 Bio Inc. | $231.3M | 2.5× | — (loss-making) | −1,928.18% (below 0%: shrinking) | n/m | +71.13% (above 0%: growing) | 100.00% | 0.00% | Compare |
| FATE Fate Therapeutics, Inc. | $230.7M | — (loss-making) | — (loss-making) | +9.18% (above 0%: growing) | n/m | +8.96% (above 0%: growing) | 100.00% | (1,495.39%) | Compare |
| LXEO Lexeo Therapeutics, Inc. | $226.6M | — (loss-making) | — (loss-making) | — | n/m | +35.58% (above 0%: growing) | 0.00% | 0.00% | Compare |
| SLGL Sol-Gel Technologies Ltd. | $224.9M | — (loss-making) | — (loss-making) | −96.58% (below 0%: shrinking) | n/m | −8.76% (below 0%: shrinking) | 100.00% | (704.23%) | Compare |
| GLSI Greenwich LifeSciences, Inc. | $224.9M | — (loss-making) | — | — | n/m | +13.14% (above 0%: growing) | 0.00% | 0.00% | Compare |
| Median of peers | $231.0M | — | — | −93.76% | — | +6.81% | 100.00% | 0.00% |
BridgeBio Oncology Therapeutics, Inc (BBOT) key facts
- BridgeBio Oncology Therapeutics, Inc (BBOT) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
- As of October 16, 2026, BBOT traded at $2.82, a market capitalization of $236.5 million.
- Return on equity was −115.3% and debt-to-equity 0.00.